Nintedanib esylate
Nintedanib esylate is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Nintedanib esylate. Available dosage forms: capsule, powder.
Drug details
- Generic Name
- Nintedanib esylate
- Brand Names
- Nintedanib esylate
- Application Number
- ANDA219926
- Sponsor
- Macleods Pharmaceuticals Limited
- NDC Codes
- 3
- Dosage Forms
- CAPSULE, POWDER
- Routes
- ORAL
- Active Ingredients
- NINTEDANIB ESYLATE
Indications and Usage
1 INDICATIONS & USAGE Nintedanib capsules are kinase inhibitor indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis Nintedanib capsules are indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib capsules are indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies ( 14.2 )].